Literature DB >> 32889006

Intranasal exposure of manganese induces neuroinflammation and disrupts dopamine metabolism in the striatum and hippocampus.

Irina Ivleva1, Nina Pestereva2, Alexander Zubov2, Marina Karpenko3.   

Abstract

Prolonged exposure to manganese (Mn) may lead to toxic effects on the central nervous system (CNS). The mechanisms underlying neuronal death from exposure to Mn are not well understood but undoubtedly involve inflammatory processes. The aim of this study was to explore the effects of long-lasting intranasal Mn exposure in rats focusing on inflammatory processes and catecholamine (dopamine, norepinephrine) levels in the striatum and hippocampus. It was found that intranasal administration by instillation of MnCl2 solution once a day for 90 days leads to impaired movement and gait. We also observed that Mn concentration increased in the hippocampus (by 30 %) and in the striatum (by 220 %), dopamine (24 %) and DOPAC (35 %) were reduced in the striatum, and dopamine (190 %) and DOPAC (220 %) levels increased with simultaneously norepinephrine reduction (30 %) in the hippocampus. Observation of cytokine mRNA revealed increased expression of both assayed cytokines (IL-1β and TNF-α) in the hippocampus. There was a 3-fold increase in the expression of IBA-1 mRNA, 2-fold increase in NFκB mRNA, and dramatic reduction in IkB mRNA in the striatum. Taken together, intranasal exposure to a high dose of MnCl2 induces neuroinflammation and neurotransmission disturbance, but the effects are specific for each studied brain region.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dopamine; Manganese; Manganism; Neuroinflammation

Mesh:

Substances:

Year:  2020        PMID: 32889006     DOI: 10.1016/j.neulet.2020.135344

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Protective effect of calpain inhibitors against manganese-induced toxicity in rats.

Authors:  I S Ivleva; A P Ivlev; N S Pestereva; T V Tyutyunnik; M N Karpenko
Journal:  Metab Brain Dis       Date:  2022-01-28       Impact factor: 3.584

Review 2.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.